In connection with the Company’s September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six (6) months after the date of issuance, or March 4, 2019.

In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in the offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018.

Common stock shares issuable upon conversion of debt/convertible securities

1,000,000

Operating lease periodic payment

$ 1,500

Annually operating lease amount

$ 104,000

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended	9 Months Ended
	Sep. 04, 2018	Aug. 08, 2017	Nov. 16, 2017	Sep. 30, 2019	Mar. 23, 2017
Private Placement [Member]
Commitments and contingencies description		(1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.
Cash commission description	In connection with the Company’s September 4, 2018 Note offering, the Agent received a cash commission for this transaction of $140,000, equal to seven (7%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase seven (7%) percent of the shares of common stock issued or issuable in this offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors, or 26,056 shares); however, will receive seven (7%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six (6) months after the date of issuance, or March 4, 2019.		In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of common stock issued or issuable in the offering (excluding shares of common stock issuable upon exercise of any warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The warrants are exercisable six (6) months after the date of issuance, or as of May 16, 2018.
SkyPharm [Member] \| Second amendment to loan facility agreement [Member]
Common stock shares issuable upon conversion of debt/convertible securities					1,000,000
Intellectual property sale agreement [Member] \| Anastasios Tsekas and Olga Parthenea Georgatsou [Member] \| On October 1, 2016 [Member]
Operating lease periodic payment				$ 1,500
Common stock shares issuable upon conversion of debt/convertible securities				200,000
Intellectual property sale agreement [Member] \| Anastasios Tsekas and Olga Parthenea Georgatsou [Member] \| On October 1, 2016 [Member] \| Conclusion of Preclinical Trials [Member]
Common stock shares issuable upon conversion of debt/convertible securities				50,000
Intellectual property sale agreement [Member] \| Anastasios Tsekas and Olga Parthenea Georgatsou [Member] \| On October 1, 2016 [Member] \| conclusion of Phase I testing [Member]
Common stock shares issuable upon conversion of debt/convertible securities				50,000
Intellectual property sale agreement [Member] \| Anastasios Tsekas and Olga Parthenea Georgatsou [Member] \| On October 1, 2016 [Member] \| Conclusion of Phase III testing [Member]
Common stock shares issuable upon conversion of debt/convertible securities				50,000
Intellectual property sale agreement [Member] \| Anastasios Tsekas and Olga Parthenea Georgatsou [Member] \| On October 1, 2016 [Member] \| Conclusion of Phase II testing [Member]
Common stock shares issuable upon conversion of debt/convertible securities				50,000
Advisory Agreement [Member] \| SkyPharm [Member] \| April 18, 2018 [Member]
Term of operating lease				10 years
Annually operating lease amount				$ 104,000